Sanofi's Dengue vaccine succeeds in Phase III

Sanofi's (SNY) vaccine for Dengue fever met the primary goal of a Phase III study by reducing incidence of the illness by 56% in a trial involving over 10,000 children in Southeast Asia.

Dengue affects up to 100M people a year, mainly in tropical areas, and is caused by a virus that is carried by mosquitoes. Symptoms include severe fever and intense joint and muscle pain, and it can be fatal.

The success of the Phase III trial follows disappointing results in a Phase II study of 4,000 children, when Sanofi's vaccine only cut dengue cases by a worse-than-expected 30%.

Shares are +2% in Paris.

From other sites
Comments (1)
  • Love_ Money
    , contributor
    Comments (462) | Send Message
    This is a significant development. Dengue affects millions in south India and is a nasty, contagious and vicious virus.
    28 Apr 2014, 05:30 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs